Answers are grounded in this paper and cite their sources.
Glioblastoma (GBM) is the most aggressive primary brain tumor, with inevitable recurrence after surgery due to infiltrative growth and an immunosuppressive microenvironment. Current therapies remain inadequate, highlighting the need for strategies that eradicate residual cells and reprogram immunity. Our preliminary analysis revealed that GLUT1 is markedly upregulated in recurrent postoperative GBM, reflecting heightened glucose demand. Based on this, we developed a biomimetic nanomedicine (FePG@CM-ANG) composed of iron ions, the GLUT1 inhibitor phloretin, and glucose oxidase (GOx), cloaked with neutrophil membranes and modified with angiopep-2 peptides for enhanced blood-brain barrier penetration and postoperative targeting. This system induces glucose deprivation, coordinating disulfidptosis via cystine accumulation and ferroptosis through disruption of the SLC7A11/GSH/GPX4 axis, while iron-mediated Fenton reactions amplify oxidative stress. The resulting immunogenic cell death promotes dendritic cell maturation, cytotoxic T-cell infiltration, and macrophage polarization. In vitro and in vivo studies confirmed potent inhibition of GBM proliferation, migration, and recurrence, accompanied by antitumor immune activation and extended survival. These findings highlight FePG@CM-ANG as a promising postoperative GBM therapy that synergistically couples metabolic reprogramming with immune modulation for enhanced tumor suppression.
No takes yet. Share an insight, caveat, or question.
Hao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: